Orasure Technologies Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Orasure Technologies Inc in the second quarter 2026?
Orasure Technologies Inc recorded a cumulative net loss of $-49 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -14.73%.

Within the Medical Equipment & Supplies industry 91 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2897 to 2901.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-16.53 %	-20.93 %	-16.94 %	-14.94 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-49	-75	-69	-60	-51
Return On Equity (TTM)	-14.73 %	-21.5 %	-18.58 %	-15.55 %	-12.66 %
OSUR's Total Ranking	# 2901	# 2897	# 2557	# 2457	#
Equity (TTM) in Millions	318	313	341	362	381
Seq. Equity Change	1.42 %	-8.07 %	-5.84 %	-4.92 %	-3.93 %
Seq. Net Income Change	-	-	-	-	-

Back to OSUR Management Effectiveness >> OSUR's 5 Years Annual ROE >> Compare OSUR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 92
Sector	# 273
Overall	# 2901

Return On Equity Statistics
High	Average	Low
14.27 %	0.11 %	-25.84 %
(Jun 30 2017)		(Mar 31 2026)

News about Orasure Technologies Inc Return on Equity ROE

OraSure Technologies Leads the Fight Against HIV: Supports National HIV Testing Day to Make a Lasting Impact

OraSure Technologies Support for National HIV Testing Day
BETHLEHEM, Pa., June 27, 2024 - OraSure Technologies, Inc. (NASDAQ: OSUR), a renowned provider of point-of-care and home diagnostic tests, along with sample management solutions, has proudly announced its unwavering support for HIV testing initiatives nationwide, in commemoration of National HIV Testing Day. This significant event is held annually on June 27th, aiming to encourage individuals across the United States to undergo HIV testing.
OraSure Technologies commitment to HIV testing aligns with their dedication to public health and advancing diagnostic solutions. By endorsing and actively participating in these testing initiatives, the company aims to facilitate the testing of thousands of individuals, initiating informed medical decisions and ultimately helping in the fight against HIV.

NOWDiagnostics Appoints Dr. Stephen S. Tang as Chairman of the Board, Bolstering Industry Expertise and Driving Innovation in Diagnostic Healthcare

NOWDiagnostics, a leading developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, has recently named Dr. Stephen S. Tang as the chairman of the company s board of directors. Dr. Tang brings a wealth of experience and industry expertise to the table, having been a longstanding veteran of the medical diagnostic industry.
Prior to joining NOWDiagnostics, Dr. Tang served as the leader of OraSure Technologies, Inc., a pioneering global company specializing in rapid at-home tests for HIV and COVID-19. During his tenure, OraSure Technologies saw notable success, with the company s stock price increasing by 1.99% from the previous year. Furthermore, the company achieved a remarkable return on equity (ROE) of 13.22% in its fourth quarter of 2023, surpassing the industry average of 2.92%.

OSUR Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	341	410	431	364	381
Y / Y Equity Change	-16.94 %	-4.72 %	18.44 %	-4.44 %	-4.53 %
Net Income in Millions	-69	-20	54	-18	-23
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-20.17 %	-4.75 %	12.46 %	-4.93 %	-6.04 %

Back to OSUR Management Effectiveness >> OSUR's 5 Years Annual ROE >> Compare OSUR ROE to its Competitors

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
OSUR's' Return on Equity at Yahoo Finance
OSUR's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for OSUR's Competitors
Subscribers only: Roe for Orasure Technologies Inc's Suppliers
Subscribers only: Return On Equity for OSUR's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:08:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.